Group 1 - The recombinant protein concept sector declined by 0.82%, ranking among the top declines in concept sectors, with notable declines in companies such as Kexing Pharmaceutical, Jieya Co., and Yipinhong [1] - Among the 14 stocks that rose, Furuida, Borui Pharmaceutical, and Saiseng Pharmaceutical had the highest increases of 10.06%, 3.54%, and 2.90% respectively [1] - The sector experienced a net outflow of 232 million yuan from main funds, with 35 stocks seeing net outflows, and five stocks experiencing outflows exceeding 30 million yuan [2] Group 2 - The top net outflow stock was Saiseng Pharmaceutical, with a net outflow of 65.48 million yuan, followed by Xilong Science, Zhongyuan Qihe, and Borui Pharmaceutical with net outflows of 61.32 million yuan, 53.12 million yuan, and 51.87 million yuan respectively [2][3] - The stocks with the highest net inflows included Furuida, Maiwei Bio, and Ruizhi Pharmaceutical, with net inflows of 189 million yuan, 39.29 million yuan, and 18.25 million yuan respectively [2] - The trading volume and price changes of various stocks in the recombinant protein sector indicate significant market activity, with Saiseng Pharmaceutical showing a trading rate of 35.58% despite the outflow [3]

中国经济网北京6月11日讯敷尔佳（301371）(301371.SZ)今日股价下跌，截至收盘，该股报26.54元，跌 幅1.70%。 敷尔佳于2023年8月1日在深交所创业板上市，发行股份数量为4,008.00万股，发行价格为55.68元/股， 保荐机构(主承销商)为中信证券股份有限公司，保荐代表人为鄢凯红、范新亮。 上市首日，敷尔佳盘中创下最高点80.04元，为该股上市以来最高价。该股目前处于破发状态。 敷尔佳首次公开发行股票的发行费用(不含增值税)合计15,988.98万元，其中保荐及承销费10,745.21万 元。 根据敷尔佳于2025年5月20日披露的2024年年度权益分派实施公告，2024年年度权益分派方案为以总股 本400,080,000股为基数，向全体在册股东按每10股派发现金股利10元人民币(含税)，合计派发现金股利 400,080,000.00元(含税)，以资本公积向全体股东每10股转增3股，共计转增120,024,000股，转增后公司 总股本为520,104,000股，剩余未分配利润结转以后年度分配，本年度不送红股。 敷尔佳首次公开发行股票募集资金总额223,165.44万元，募集资金净额 ...

Group 1 - The A-share port and shipping sector showed strong performance in the afternoon, with significant gains across various companies [1] - China National Aviation Corporation's ocean shipping arm surged over 27%, indicating robust market interest [1] - Companies such as Ningbo Shipping, Ningbo Ocean, Nanjing Port, and Lianyungang all reached their daily limit up, reflecting a bullish sentiment in the sector [1] Group 2 - Jinjiang Shipping and Phoenix Shipping both increased by over 6.5%, contributing to the overall positive trend in the industry [1] - Chongqing Port and Xiamen Port also experienced gains exceeding 5.5%, further highlighting the strength of the port and shipping sector [1]

敷尔佳（301371）公告，公司第三类医疗器械产品"重组Ⅲ型人源化胶原蛋白贴敷料"通过临床试验伦理 审查，并在黑龙江省药品监督管理局完成备案，已进入临床试验阶段。该产品用于激光、光子术后创面 修复辅助治疗及敏感性皮肤患者皮肤屏障功能损伤修复。目前，国内外应用于医美领域的同类医疗器械 产品及生产企业相对较少，市场处于快速发展阶段，国内生产及销售情况增长较快，市场需求持续增 长，市场潜力非常可观。 ...

证券代码：301371 证券简称：敷尔佳 公告编号：2025-020 哈尔滨敷尔佳科技股份有限公司 关于第三类医疗器械产品完成临床试验备案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，哈尔滨敷尔佳科技股份有限公司（以下简称"公司"）在研产品"重 组Ⅲ型人源化胶原蛋白贴敷料"通过该产品临床试验所有中心伦理委员会的伦理 审查，并在黑龙江省药品监督管理局完成分中心盘锦辽油宝石花医院的医疗器械 临床试验备案，公司在研产品"重组Ⅲ型人源化胶原蛋白贴敷料"已经可以开展 临床试验。具体情况公告如下： 一、基本情况 （一）临床试验备案项目一 1、申办者：哈尔滨敷尔佳科技股份有限公司 2、申办地址：哈尔滨市松北区美谷路 500 号 3、试验名称：评价重组Ⅲ型人源化胶原蛋白贴敷料用于激光、光子术后创 面修复辅助治疗的有效性和安全性 4、试验目的：通过与广州创尔生物技术股份有限公司生产的胶原贴敷料对 比，评价公司研制的重组Ⅲ型人源化胶原蛋白贴敷料（MRC-W-T）用于激光、光 子术后面部皮肤创面修复辅助治疗的有效性、安全性 5、试验用医疗器械名称：重组Ⅲ型人源化胶原 ...

Core Viewpoint - The cosmetics retail sales in China for January to April 2025 showed a year-on-year increase of 4%, underperforming the overall retail market by 0.7 percentage points, but this represents an improvement compared to 2024. The industry is characterized by four key trends: innovation in personal care products, breakthroughs in ingredient technology, rising emotional consumption, and the continuation of affordable consumption [1][3]. Investment Recommendations - The company recommends increasing holdings in the personal care sector, highlighting quality companies that benefit from product innovation and opportunities in Douyin channels, with key recommendations including Ruoyuchen (003010), Dengkang Oral (001328), and Runben Co. [2] - In the beauty sector, structural opportunities are identified, with key recommendations for companies like Jinbo Biological, Juzi Biological, and Marubi Co. that are positioned to benefit from the collagen restructuring trend. Additionally, brands like Maogeping, Shumei Co., Proya (603605), and Shanghai Jahwa (600315) are expected to gain from the overall increase in domestic market share [2]. - Companies expected to bottom out and potentially see a turning point include Lafang Household (603630), Shuiyang Co. (300740), Betaini (300957), Furuida (600223), Huaxi Biological, Fulejia (301371), Meilitiantian Medical Health, and Qingsong Co. (300132) [2]. Industry Overview - Demand remains stable, with the rise of domestic brands in the beauty and personal care sectors accelerating. The cosmetics retail sales for January to April 2025 increased by 4% year-on-year, which is a 0.7 percentage point underperformance compared to the overall retail market, but shows improvement from 2024. The overall demand is stable, with leading domestic brands performing well and the rise of new domestic brands spreading from beauty to personal care categories [3][4]. Trends - The industry is witnessing several trends: 1) Personal care transformation with new products in traditional categories, supported by content e-commerce creating a favorable environment for new product launches [4]. 2) Ingredient innovation, particularly in collagen restructuring, with various types and structural innovations expanding application scenarios [4]. 3) Emotional consumption, where cultural, stylistic, and experiential demands are driving the growth of domestic trends in cosmetics and fragrances [4]. 4) Affordable consumption, where the trend for cost-effectiveness continues under supply-demand resonance, benefiting strong supply chains and well-operated brands [4]. Key Companies - Looking ahead to 2025, the market risk appetite is expected to recover significantly. The beauty sector is characterized by substantial changes and a clear trend of rising domestic brands, indicating strong growth potential and leadership in new consumption [5]. The differentiation among brands is increasing, emphasizing the selection of high-growth targets driven by product innovation and attention to marginal improvements [5].

Group 1 - The cosmetics sector is experiencing a rise, with Betaini (300957) increasing by over 10% [1] - Other companies such as Babi Co., Water Sheep Co. (300740), Fulejia (301371), Lafang Jiahua (603630), and Furida (600223) are also seeing gains [1]

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company reported a revenue of 2.02 billion yuan in 2024, representing a year-on-year growth of 4.3%, while the net profit attributable to shareholders was 660 million yuan, down 11.8% year-on-year. In Q1 2025, the revenue was 300 million yuan, a decline of 26.4% year-on-year, and the net profit attributable to shareholders was 90 million yuan, down 39.8% year-on-year [2][4] Summary by Sections Financial Performance - In 2024, the company achieved a total revenue of 2.02 billion yuan, with a net profit of 660 million yuan. The revenue growth was primarily driven by the cosmetics segment, which saw a 7.5% increase year-on-year, while the medical device segment remained stable with a 0.3% increase [9] - For Q1 2025, the company experienced a significant revenue drop of 26.4% year-on-year, attributed to proactive channel and product optimization efforts [9] Product and Channel Strategy - The company has successfully expanded its product offerings, with several products achieving annual sales exceeding 100 million yuan. The online sales channel has also seen substantial growth, with a 20% increase in revenue [9] - The company is focusing on enhancing its brand presence in e-commerce platforms, which has contributed to a significant increase in online sales [9] Profitability Metrics - The overall gross margin for 2024 was 82%, with a slight decrease of 0.5 percentage points. The net profit margin decreased by 6 percentage points to 32.8%, primarily due to an increase in sales expense ratio [9] - In Q1 2025, the net profit margin further declined by 6.7 percentage points, influenced by a rise in sales expenses and adjustments in product pricing [9] Future Outlook - The company is expected to stabilize its revenue and profitability through the formation of repeat purchases of core products and the gradual establishment of e-commerce strategies. EPS forecasts for 2025, 2026, and 2027 are projected to be 1.74 yuan, 1.89 yuan, and 2.05 yuan respectively [9]

Market Overview - The Shanghai Composite Index rose by 0.38% on May 20, with 27 out of the 28 sectors experiencing gains, led by the beauty and personal care sector, which increased by 2.50% [2] - The defense and military industry and coal sector were the only sectors to decline, with decreases of 0.50% and 0.33% respectively [2] Capital Flow Analysis - The main capital flow showed a net outflow of 1.037 billion yuan across the two markets, with 18 sectors seeing net inflows [2] - The electronics sector had the highest net inflow, amounting to 2.673 billion yuan, and it rose by 0.71% [2] - The pharmaceutical and biotechnology sector also performed well, with a daily increase of 1.64% and a net inflow of 1.555 billion yuan [2] Beauty and Personal Care Sector - The beauty and personal care sector saw a daily increase of 2.50%, with a net inflow of 268 million yuan [3] - Out of 31 stocks in this sector, 24 stocks rose, including 2 that hit the daily limit, while 6 stocks declined [3] - The top three stocks by net inflow were: - Reliable Co., with a net inflow of 115 million yuan and a price increase of 12.14% [3] - Yiyi Co., with a net inflow of 101 million yuan and a price increase of 10.02% [3] - Aimeike, with a net inflow of 78.9 million yuan and a price increase of 3.93% [3] Notable Stocks in Beauty and Personal Care Sector - The following stocks had significant capital flows: - Reliable Co. (12.14% increase, 31.85% turnover, 114.57 million yuan inflow) [4] - Yiyi Co. (10.02% increase, 17.90% turnover, 100.68 million yuan inflow) [4] - Aimeike (3.93% increase, 2.81% turnover, 78.90 million yuan inflow) [4] - Conversely, the stocks with the highest net outflows included: - Qingdao King (5.23% decrease, 27.12% turnover, 162.54 million yuan outflow) [4] - Qingsong Co. (1.50% decrease, 24.11% turnover, 54.19 million yuan outflow) [4] - Fulejia (10.77% increase, 16.50% turnover, 20.36 million yuan outflow) [4]

Market Overview - The Shanghai Composite Index closed at 3380.45 points, above the five-day moving average, with a gain of 0.38% [1] - The total trading volume of A-shares reached 752.206 billion yuan [1] Stocks Performance - A total of 730 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Fulejia (Code: 301371) with a deviation rate of 8.24% and a daily increase of 12.17% [1] - Huahai Pharmaceutical (Code: 600521) with a deviation rate of 7.56% and a daily increase of 10.00% [1] - Aofei Entertainment (Code: 002292) with a deviation rate of 7.46% and a daily increase of 10.02% [1] Deviation Rate Rankings - The top stocks with the highest deviation rates from the five-day moving average include: - Fulejia: Latest price 36.05 yuan, five-day moving average 33.31 yuan [1] - Huahai Pharmaceutical: Latest price 15.62 yuan, five-day moving average 14.52 yuan [1] - Aofei Entertainment: Latest price 9.77 yuan, five-day moving average 9.09 yuan [1] - Other notable stocks with high daily turnover rates include: - Huifeng Diamond (Code: 839725) with a daily increase of 9.56% and a turnover rate of 14.77% [1] - Beiningmei (Code: 002570) with a daily increase of 10.07% and a turnover rate of 22.33% [1]